© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Titan Pharmaceuticals, Inc. (TTNP) stock declined over -2.16%, trading at $3.40 on NASDAQ, down from the previous close of $3.48. The stock opened at $3.43, fluctuating between $3.32 and $3.56 in the recent session.
South San Francisco, CA 94080-1958
United States
Website: https://www.titanpharm.comContact: 650 244 4990Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Employees | 4 |
Beta | 1.12 |
Sales or Revenue | $184.00K |
5Y Sales Change% | -0.992% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) stock price is $3.40 in the last trading session. During the trading session, TTNP stock reached the peak price of $3.56 while $3.32 was the lowest point it dropped to. The percentage change in TTNP stock occurred in the recent session was -2.16% while the dollar amount for the price change in TTNP stock was -$0.08.
The NASDAQ listed TTNP is part of Biotechnology industry that operates in the broader Healthcare sector. Titan Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Marc Rubin M.D.
Executive Director
Jennifer Kiernan
Executive Assistant to Chief Executive Officer & Investor Communications Coordinator
Joe Schrei
Executive Director of Commercial Operations
Mr. Mike Fritz
National Sales Director
Dr. Katherine L. Beebe-DeVarney Ph.D.
Pres, Chief Operating Officer & Director
TTNP's closing price is 12.21% higher than its 52-week low of $3.03 where as its distance from 52-week high of $14.80 is -77.03%.
Number of TTNP employees currently stands at 4.
Official Website of TTNP is: https://www.titanpharm.com
TTNP could be contacted at phone 650 244 4990 and can also be accessed through its website. TTNP operates from 400 Oyster Point Boulevard, South San Francisco, CA 94080-1958, United States.
TTNP stock volume for the day was 21.54K shares. The average number of TTNP shares traded daily for last 3 months was 27.93K.
The market value of TTNP currently stands at $3.11M with its latest stock price at $3.40 and 914.23K of its shares outstanding.